close

Clinical Trials

Date: 2013-09-03

Type of information:

phase: 1

Announcement: first administration to human

Company: Imaxio (France)

Product: MVA85A-IMX313

Action mechanism: Imaxio\'s proprietary antigen re-engineering technology, IMX313, is designed to enhance the immune response and, therefore, the effectiveness of each vaccine in which it is used. IMX313 brings significant potential as a solution to develop vaccines and immunotherapies for major indications. The technology was designed in response to the challenge in increasing the effectiveness of some human and animal health candidates, and is currently used for the development of vaccine candidates indicated for influenza, Staphylococcus aureus infection, tuberculosis and malaria.

Disease: tuberculosis

Therapeutic area: Infectious diseases

Country: UK

Trial details: This phase I trial is a dose escalation study that aims to assess the safety and immunogenicity of the tuberculosis vaccine candidate MVA85A-IMX313, a viral vector vaccine encoding the well-known tuberculosis antigen 85A which is fused to Imaxio’s IMX313. The study will be performed in the UK and led by Prof. Helen McShane from the Jenner Institute at Oxford University. (NCT01879163)

Latest news:

* On September 3, 2013, Imaxio, a biopharmaceutical company specializing in vaccines and genomics, has announced that IMX313, its proprietary pro-immunogenic technology, has been administered for the first time to humans in a tuberculosis vaccine phase I clinical study. The trial is being conducted by the Jenner Institute at Oxford University, England. As the currently available vaccine, BCG, is largely ineffective at protecting against adult pulmonary disease in endemic areas, the MVA85A vaccine candidate has been designed to enhance BCG’s protective efficacy. Though first studies of MVA85A were promising, a recent phase II clinical trial revealed that the vaccine candidate did not offer extra protection against TB in South African infants who had already received the BCG vaccine. The Jenner Institute is investigating a number of options to see if the immune response generated by MVA85A can be improved. The Jenner Institute identified IMX313 as one of the best vaccine technologies to enhance immune responses in a comparison study funded by a grant from the Foundation for the National Institutes of Health through the Grand Challenges in Global Health initiative, and is now starting to evaluate it in humans in combination with MVA85A.

Is general: Yes